Cell-specific modulation of drug resistance in acute myeloid leukemic blasts by diphtheria fusion toxin, DT388-GMCSF

Bioconjugate Chemistry

Volumn 9, Issue 4, 1998, Pages 490-496

  Frankel, Arthur E ^a,b   Hall, Philip D ^b   McLain, Chris ^a   Safa, Ahmad R ^b   Tagge, Edward P ^a   Kreitman, Robert J ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTICS; ANTIBODIES; BIOSYNTHESIS; CELL CULTURE; CHEMOTHERAPY; CYTOTOXICITY; METABOLITES; MODULATION;

ACUTE MYELOID LEUKEMIA; CELL LINES; DOXORUBICIN; DRUG-RESISTANCE; FUSION TOXINS; MULTIDRUG RESISTANCE; OVEREXPRESSIONS; RADIOCHEMOTHERAPY; TARGETED DELIVERY; TREATMENT FAILURE;

GLYCOPROTEINS;

EID: 0032127605     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc980015a     Document Type: Article

References (39)

1. Parker, S., Tong, T., Bolden, S., and Wingo, P. (1997) Cancer statistics, 1997. Ca - Cancer J. Clin. 47, 5-12.
2. Schiffer C. (1997) Acute myeloid leukemia in adults. Cancer Medicine (J. Holland, E. Frei, R. Bast, D. Kufe, D. Marton, and R. Weichselbaum, Eds.) pp 2617-2633, Lea & Febiger, Philadelphia.
3. List, A. (1996) Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 10, 937-944.
4. Solary, E., Witz, B., Caillot, D., Moreau, P., Desablens, B., Cahn J. Y., Sadoun, A., Pignon, B., Berthou, C., Maloisel, F., Guyotat, D., Casassus, P., Ifrah, N., Lamy, Y., Audhuy, B., Colombat, P., and Harousseau, J. L. (1996) Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 88, 1198-1204.
5. Muller, C., Laurent, G., and Ling, V. (1995) P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J. Cell Physiol. 163, 538-544.
6. Shen, H., Ranganathan, S., Kuzmich, S., and Tew, K. D. (1995) Influence of ethacrynic acid on glutathione S-transferase pi transcript and protein half-lives in human colon cancer cells. Biochem. Pharm. 50, 1233-1245.
7. Blagosklonny, M., Alvarez, M., Fojo, A., and Neckers, L. (1996) Bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. Leuk. Res. 20, 101-112.
8. Pirker, R., Wallner, J., Geissler, K., Kinkesch, W., Haas O, Bettelheim, P., Hopfner, M., Scherrer, R., Valent, P., Havelec, L., Ludwig, H., and Lechner, K. (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J. Natl. Cancer Inst. 83, 708-712.
9. Russo, D., Marie, J. P., Zhou, D. C., Faussat, A. M., Melli, C., Damiani, D., Michelutti, A., Michieli, M., Fanin, R., and Baccarani, M. (1994) Evaluation of the clinical relevance of the anionic glutathione S-transferase (GST pi) and multidrug resistance (mdr-1) gene coexpression in leukemias and lymphomas. Leuk. Lymph. 15, 453-461.
10. Maung, Z., MacLean, F., Reid, M., Pearson, A., Proctor, S., Hamilton, P., and Hall, A. (1994) The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br. J. Haematol. 88, 105-115.
11. Ghetie, M. A., Tucker, K., Richardson, J., Uhr, J. W., and Vitetta, E. S. (1994) Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood 84, 702-718.
12. O'Connor, R., Liu, C., Ferris, C. A., Guild, B. C., Teicher, B. A., Corvi, C., Liu, Y., Arceci, R. J., Goldmacher, V. S., Lambert, J. M., and Blattler, W. A. (1995) Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. Blood 86, 4286-4294.
13. Lidor, Y. J., O'Briant, K. C., Xu, F. J., Hamilton, T. C., Ozols, R. F., and Bast, R. C. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. (1993). J. Clin. Invest. 92, 2440-2453.
14. Ghetie, M. A., Podar, E. M., Gordon, B. E., Pantazis, P., Uhr, J. W., and Vitetta, E. (1996) Combination immunotoxin treatment and chemotherapy in scid mice with advanced, disseminated Daudi lymphoma. Int. J. Cancer 68, 93-105.
15. Uckun, F., Gajl-Peczalska, K., Myers, D., Ramsay, N., Kersey, J., Colvin, M., and Vallera, D. (1987) Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxy-cyclophosphamide against fresh leukemic marrow progenitor cells. Blood 69, 361-377.
16. Weil-Hillman, G., Uckun, F., Manske, J., and Vallera, D. (1987) Combined immunochemotherapy of human solid tumors in nude mice. Cancer Res. 47, 579-588.
17. Pearson, J., FitzGerald, D., Willingham, M., Wiltrout, R., Pastan, I., and Longo, D. (1989) Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenograft in nude mice. Cancer Res. 49, 3562-3571.
18. Jansen, B., Kersey, J., Jaszcz, W., Gunther, R., Nguyen, D., Chelstrom, L., Tuelahlgren, L., and Uckun, F. (1993) Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide. Leukemia 7, 290-301.
19. Frankel, A. E., Hall, P. D., Burbage, C. Vesely, J., Willingham, M., Bhalla, K., and Kreitman, R. J. (1997) Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin-granulocyte-macrophage colony stimulating factor (GMCSF) fusion protein. Blood 90, 3654-3661.
20. Kreitman, R. J., and Pastan, I. (1997) Recombinant toxins containing human GM-CSF and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood 90, 242-250.
21. Perentesis, J., Waddick, K., Bendel, A., Shao, Y., Warman, B., Chandan-Langlie, M., and Uckun, F. M. (1997) Induction of apoptosis in multidrug-resistant and radiation-resistant acute myeloid leukemia cells by a recombinant fusion toxin directed against the human granulocyte-macrophage colony-stimulating factor receptor. Clin. Cancer Res. 3, 347-360.
22. Roy, D., Griffin, J., Belvin, M., Blattler, W. Lambert, J., and Ritz, J. Anti-MY9-blocked ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. (1991) Blood 77, 2404-2410.
23. Kabral, A., Bradstock, K. F., Grimsley, P., Favaloro, E. J. (1988) Immunophenotype of clonogenic cells in myeloid leukemia. Leuk. Res. 12, 51-58.
24. Kelleher, C., Wong, G., Clark, S., Schendel, P., Minden, M., and McCulloch, E. (1988) Binding of iodinated recombinant human GM-CSF to the blast cells of acute myeloblastic leukemia. Leukemia 2, 211-231.
25. Dalton, W. T., Ahearn, M., McCredie, K. B., Freireich, E. J., Stass, S. A., and Trujillo, J. M. (1988) HL-60 cell line was derived from a patient with FAB-M2 and not FAB-M3. Blood 71, 242-245.
26. McGrath, T., Latoud, C., Arnold, S. T., Safa, A. R., Felsted, R. L., and Center, M. S.(1989) Mechanism of multidrug resistance of HL60 cells. Analysis of resistance associated membrane proteins and levels of mdr gene expression. Biochem. Pharm. 38, 3611-3618.
27. Berenbaum, M. J. (1989) What is synergy? Pharm. Rev. 41, 93-123.
28. Forman, S. J., Schmidt, G. M., and Nademanee, A. P. (1991) Allogeneic marrow transplantation as therapy for primary induction failure of patients with acute leukemia. J. Clin. Oncol 9, 1570-1585.
29. Gandhi, V., Estey, E., Keating, M. J., and Plunkett, W. (1993) Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during chemotherapy. J. Clin. Oncol. 11, 116-129.
30. Seiter, K., Feldman, E. J., Halicka, H. D., Traganos, F., Darzynkiewicz, Z., Lake, D., and Ahmed, T. (1997) Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.J Clin Oncol 15, 44-59.
31. Kantarjian, H. M., Estey, E. H., and Keating, M. A. (1996) New chemotherapeutic agents in acute myeloid leukemia. Leukemia 10 (Suppl. 1), S4-S8.
32. List, A. F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M., and Dalton, W. (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. 11, 1652-1667.
33. Frankel, A. E., FitzGerald, D., Siegall, C., and Press, O. W. (1996) Advances in immunotoxin biology and therapy: a summary of the fourth international symposium on immunotoxins. Cancer Res. 56, 926-936.
34. Hall, P. D., Kreitman, R. J., Willingham, M. C., and Frankel, A. E. (1998) Pharmacology and pharmacokinetics of DT388-GM-CSF, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony stimulating factor (GM-CSF), in C57BL/6 mice. Toxicol. Appl. Pharm. (In press).
35. Sievers, E., Appelbaum, F., Spielberger, R., Forman, S., Flowers, D., Berger, M., Shannon-Doras, K., and Bernstein, I. (1997) Dose escalation phase I study of recombmant engineered human anti-CD33 antibody-calicheamicin drug conjugate (CMA-676) in patients with relapsed or refractory acute myeloid leukemia (AML). Blood 90, 504a.
36. O'Brien, M. L., and Tew, K. D. (1996) Glutathione and related enzymes in multidrug resistance. Eur J. Cancer 32A, 967-980.
37. Pastan, I. H. (1997) Tumor immunotoxins: technology closes in on potential. Adv. .Oncol. 13, 3-12.
38. Chan, C. H., Blazar, B. R., Eider, C. R., Kreitman, R. J., Vallera, D. A. (1995) A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells. Blood 86, 2732-2740.
39. Leith, C. P., Chen, I. M., Kopecky, K. J., Appelbaum, F. R., Head, D. R., Godwin, J. E., Weick, J. K., and Willman, C. L. (1995) Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/Efflux+ and MDR+/Efflux-cases. Blood 86, 2329-2342.